Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for clarity on Utah Medical Products’ highly specialized business? Investors often start with where to find Utah Medical Products insider trading Form 4 transactions and end up digging through hundreds of pages about FDA clearances and manufacturing margins. This page brings everything together—Utah Medical Products SEC filings explained simply, one click away.
Use Stock Titan’s AI-powered summaries to cut through technical language. Whether you need the latest Utah Medical Products quarterly earnings report 10-Q filing to track neonatal device sales, or want Utah Medical Products Form 4 insider transactions real-time before market open, each document arrives seconds after EDGAR posts. Our engine highlights segment revenue swings, new product approvals and legal updates so you can focus on decisions, not page counts.
Wonder how leadership is aligned? The platform flags Utah Medical Products executive stock transactions Form 4 and cross-links them to compensation details in the Utah Medical Products proxy statement executive compensation. Need the bigger picture? The Utah Medical Products annual report 10-K simplified lays out gross-margin trends across disposable versus reusable lines, while the Utah Medical Products earnings report filing analysis spotlights R&D intensity. Unexpected news surfaces fast through our AI notes on Utah Medical Products 8-K material events explained. All filings—10-K, 10-Q, 8-K, S-8, plus every Form 4—stream into one dashboard, complete with plain-English takeaways, downloadable tables and historical comparisons. Understanding Utah Medical Products SEC documents with AI has never been so direct.
BlackRock Portfolio Management LLC filed Amendment No. 1 to Schedule 13G for Fortrea Holdings Inc. (FTRE) covering holdings as of 30 Jun 2025. The firm reports beneficial ownership of 804,040 common shares, equal to 0.9 % of outstanding stock, placing the position well below the 5 % threshold that would trigger additional reporting requirements.
BlackRock has sole voting power over 714,353 shares and sole dispositive power over the full 804,040-share stake; it reports no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business, without intent to influence control. Because ownership is under 5 %, the filer confirms compliance with Item 5 and notes that no single client owns more than 5 % of FTRE. The document is certified by Managing Director Spencer Fleming on 15 Jul 2025.
FAQ
What is the current stock price of Utah Med Prods (UTMD)?
What is the market cap of Utah Med Prods (UTMD)?
What is the core business of Utah Medical Products Inc.?
Which product categories are included in UTMD's portfolio?
How does UTMD ensure device quality and reliability?
What markets and customer segments does UTMD serve?
How does UTMD differentiate itself from competitors?
What role do OEM partnerships play in UTMD's business model?
How is operational efficiency maintained at UTMD?
In which clinical environments are UTMD's products primarily used?
